Company intelligence / Profile preview

Kineta Four

Seattle, Washington, United States

Ownership: Private
Development stage: Other

Overview

Kineta suspended enrollment in its VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 in February 2024 following a corporate restructuring. The trial had been evaluating KVA12123 as both monotherapy and in combination with checkpoint inhibitors, demonstrating strong tumor growth inhibition in preclinical models without evidence of cytokine release syndrome in clinical participants.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBispecific antibody
Industry: Biotech

Beyond the preview

Go deeper on Kineta Four.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kineta Four.

Explore the full profile